Clinical Use of Rifampicin in Combination for Non-Mycobacterial Infections: A Survey of Published Evidence
- 1 May 1979
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 7 (3) , 179-186
- https://doi.org/10.1177/030006057900700304
Abstract
The literature on the clinical use of rifampicin in combination for the treatment of non-mycobacterial diseases is reviewed. From the published evidence, the most promising associations are, for staphylococcal infections, gentamicin, erythromycin, kanamycin and fusidic acid. In the field of Gram-negative infections, Pseudomonas-induced sepsis in particular, data are not so impressive but promising results have been obtained with the associated use of rifampicin and gentamicin or colistin. Some systemic fungal diseases may be successfully treated with rifampicin in combination with amphotericin-B. Although only few reports are available on this subject, the importance of such an application is stressed in view of the severity of these diseases and of the lack of appropriate treatments.This publication has 19 references indexed in Scilit:
- Staphylococcus aureus EndocarditisPublished by American Medical Association (AMA) ,1978
- PENICILLIN-TOLERANT STAPHYLOCOCCUS AUREUSThe Lancet, 1977
- Treatment of Chronic Salmonella CarriersChemotherapy, 1977
- Rifampin-Amphotericin B Synergism?Annals of Internal Medicine, 1976
- Ventriculojugular shunt nephritis with Corynebacterium bovisThe American Journal of Medicine, 1975
- Choix d'une antibiothérapie antistaphylococcique bactéricideMedecine Et Maladies Infectieuses, 1975
- Endocarditis caused by a psittacosis agent.Heart, 1974
- Pseudomonas aeruginosa endocarditis: Report of a case, with review of the literatureThe American Journal of Medicine, 1973
- Oral antibiotic cure of staphylococcal endocarditisPublished by Oxford University Press (OUP) ,1973
- METHICILLIN-RESISTANT STAPHYLOCOCCIThe Lancet, 1968